

Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2022

<https://marketpublishers.com/r/AEB10461FD9AEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: AEB10461FD9AEN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2022" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Alpha 1 adrenergic receptor antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Alpha 1 adrenergic receptor antagonist Understanding

Alpha 1 adrenergic receptor antagonist: Overview

Alpha-1–adrenergic receptors (ARs) are G protein–coupled receptors activated by catecholamines. The alpha-1A and alpha-1B subtypes are expressed in mouse and human myocardium, whereas the alpha-1D protein is found only in coronary arteries. The alpha-1 adrenergic receptors activate the Gq/11 family of G proteins leading to the dissociation of the α and $\beta\gamma$ subunits and the subsequent stimulation of the enzyme phospholipase C. This enzyme hydrolyzes phosphatidylinositol 1,2-bisphosphate in the membrane producing inositol trisphosphate (IP3) and diacylglycerol. These molecules act as second messengers mediating intracellular Ca^{2+} release via the IP3 receptor

and activating protein kinase C. Alpha-1-adrenoreceptor antagonist drugs have the immediate attraction that there are no patient co-morbidities that constitute absolute contraindications to their use. Thus, alpha blockers can safely and appropriately be administered to hypertensive patients with concomitant disease states such as diabetes mellitus or obstructive airway disease or renal impairment.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alpha 1 adrenergic receptor antagonist R&D. The therapies under development are focused on novel approaches for Alpha 1 adrenergic receptor antagonist.

Alpha 1 adrenergic receptor antagonist Emerging Drugs Chapters

This segment of the Alpha 1 adrenergic receptor antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alpha 1 adrenergic receptor antagonist Emerging Drugs

TNX-102 SL: Tonix Pharmaceuticals

TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. Tonix is developing TNX-102 SL* as a potential treatment for the symptoms of Fibromyalgia. It is currently in Phase 3 clinical development. TNX-102 SL targets mechanisms which are associated with disturbed sleep. It is believed that increasing sleep quality in fibromyalgia may facilitate the body's adaptive ability to modulate the perception of pain.

Roluperidone: Minerva Neurosciences

Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT_{2A}. When 5-HT_{2A} is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation and thought and movement disorders, as well as the side effects associated with antipsychotic treatments, can be minimized. Roluperidone has also been designed to block a specific subtype of sigma receptor called sigma₂, which is involved in movement control, psychotic symptom control and learning and memory. Blocking sigma₂, along with blocking the α adrenergic subtypes α 1A, and to a lesser extent α 1B, also increases calcium levels in neurons in the brain, which can improve memory. Pre-clinical findings provide evidence of the effect of roluperidone on Brain-Derived Neurotrophic Factor (“BDNF”), which has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning and memory.

Further product details are provided in the report.....

Alpha 1 adrenergic receptor antagonist: Therapeutic Assessment

This segment of the report provides insights about the different Alpha 1 adrenergic receptor antagonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Alpha 1 adrenergic receptor antagonist

There are approx. 12+ key companies which are developing the Alpha 1 adrenergic receptor antagonist. The companies which have their Alpha 1 adrenergic receptor antagonist drug candidates in the most advanced stage, i.e. Phase III include, Tonix Pharmaceuticals.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Alpha 1 adrenergic receptor antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alpha 1 adrenergic receptor antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Alpha 1 adrenergic receptor antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha 1 adrenergic receptor antagonist drugs.

Alpha 1 adrenergic receptor antagonist Report Insights

Alpha 1 adrenergic receptor antagonist Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Alpha 1 adrenergic receptor antagonist Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Alpha 1 adrenergic receptor antagonist drugs?

How many Alpha 1 adrenergic receptor antagonist drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha 1 adrenergic receptor antagonist?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha 1 adrenergic receptor antagonist therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Alpha 1 adrenergic receptor antagonist and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Tonix Pharmaceuticals

Minerva Neurosciences

INNOPHARMAX

Bristol-Myers Squibb

Kissei Pharmaceutical

Pharmazz

Ocularis Pharma

Kinnov Therapeutics

Ache Laboratories

Ildong Pharmaceutical

GL PharmTech

Jeil Pharmaceutical

Chong Kun Dang

Ocuphire Pharma

Fabre-Kramer Pharmaceuticals

Key Products

TNX-102 SL

Roluperidone (MIN-101)

C 08001

Aripiprazole

FKF 02SC

Silodosin

Cenchaquine

Phentolamine

KT 110

Phentolamine/pilocarpine

ACH 000029

Tadalafil/tamsulosin

GL2701 CKD-825

JLP-1207

Contents

Introduction

Executive Summary

Alpha 1 adrenergic receptor antagonist: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Alpha 1 adrenergic receptor antagonist – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

TNX-102 SL: Tonix Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

FKF 02SC: Fabre-Kramer Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Cenchaquine: Pharmazz

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
ACH 000029: Ache Laboratories
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Alpha 1 adrenergic receptor antagonist Key Companies
Alpha 1 adrenergic receptor antagonist Key Products
Alpha 1 adrenergic receptor antagonist- Unmet Needs
Alpha 1 adrenergic receptor antagonist- Market Drivers and Barriers
Alpha 1 adrenergic receptor antagonist- Future Perspectives and Conclusion
Alpha 1 adrenergic receptor antagonist Analyst Views
Alpha 1 adrenergic receptor antagonist Key Companies
Appendix

I would like to order

Product name: Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/AEB10461FD9AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AEB10461FD9AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970